LIVIVO - Search results -

Search results

Result 1 - 10 of total 127

Search options

Article: [NOVEL TECHNOLOGIES AND FUTURE TRENDS IN TRANSLATIONAL RESEARCH IN ONCOLOGY].

Ligumsky, Hagai / Bar, Yael / Wolf, Ido / Bar, Kfir

2024 Volume 163, Issue 2, Page(s) 102–108

Abstract: Introduction: Translational research in medicine has undergone significant changes in the last decade, primarily due to the remarkable technological advancements made during this period. Oncology research is at the forefront of translational research in ...

Abstract	Introduction: Translational research in medicine has undergone significant changes in the last decade, primarily due to the remarkable technological advancements made during this period. Oncology research is at the forefront of translational research in medicine and is heavily influenced by these changes. In this article, we briefly review the technologies that form the basis for the "next generation of translational research" in oncology in the coming decades, as well as the emerging trends in translational research in oncology through the implementation of these technologies.
MeSH term(s)	Humans ; Translational Research, Biomedical ; Medical Oncology ; Medicine
Language	Hebrew
Publishing date	2024-02-29
Publishing country	Israel
Document type	English Abstract ; Journal Article
ZDB-ID	953872-0
ISSN	0017-7768
ISSN	0017-7768
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 291: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Place of Death for Israeli Cancer Patients Over a 20-Year Period: Reducing Hospital Deaths, but Barriers Remain.

Shalev Many, Yuval / Shvartzman, Pesach / Wolf, Ido / Silverman, Barbara G

The oncologist

2023 Volume 28, Issue 11, Page(s) e1092–e1098

Abstract: Background: Cancer remains a leading cause of mortality worldwide. While the main focus of palliative care (PC) is quality of life, the elements that comprise the quality of death are often overlooked. Dying at home, with home-hospice-care (HHC) support, ...

Abstract	Background: Cancer remains a leading cause of mortality worldwide. While the main focus of palliative care (PC) is quality of life, the elements that comprise the quality of death are often overlooked. Dying at home, with home-hospice-care (HHC) support, rather than in-hospital, may increase patient satisfaction and decrease the use of invasive measures. We examined clinical and demographic characteristics associated with out-of-hospital death among patients with cancer, which serves as a proxy measure for HHC deaths. Methods: Using death certification data from the Israel Central Bureau of Statistics, we analyzed 209,158 cancer deaths between 1998 and 2018 in Israel including demographic information, cause of death, and place of death (POD). A multiple logistic regression model was constructed to identify factors associated with out-of-hospital cancer deaths. Results: Between 1998 and 2018, 69.1% of cancer deaths occurred in-hospital, and 30.8% out-of-hospital. Out-of-hospital deaths increased by 1% annually during the study period. Older patients and those dying of solid malignancies were more likely to die out-of-hospital (OR = 2.65, OR = 1.93, respectively). Likelihood of dying out-of-hospital varied with area of residency; patients living in the Southern district were more likely than those in the Jerusalem district to die out-of-hospital (OR = 2.37). Conclusion: The proportion of cancer deaths occurring out-of-hospital increased during the study period. We identified clinical and demographic factors associated with POD. Differences between geographical areas probably stem from disparity in the distribution of PC services and highlight the need for increasing access to primary EOL care. However, differences in age and tumor type probably reflect cultural changes and suggest focusing on educating patients, families, and physicians on the benefits of PC.
MeSH term(s)	Humans ; Terminal Care ; Israel ; Quality of Life ; Neoplasms ; Hospices
Language	English
Publishing date	2023-06-01
Publishing country	England
Document type	Journal Article
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1093/oncolo/oyad141
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [EFFECT OF COVID-19 ON ONCOLOGY PATIENTS IN ISRAEL: FROM THE EXPERIENCE OF A TERTIARY CENTER].

Waissengrin, Barliz / Aks, Rona / Wolf, Ido

Harefuah

2022 Volume 161, Issue 1, Page(s) 9–13

Abstract: Introduction: The Covid-19 pandemic affects cancer patients in a variety of ways, ranging from delay in diagnosis and treatment to directly causing serious illness. To date, data on the characteristics of Covid-19 disease among cancer patients in Israel ...

Abstract	Introduction: The Covid-19 pandemic affects cancer patients in a variety of ways, ranging from delay in diagnosis and treatment to directly causing serious illness. To date, data on the characteristics of Covid-19 disease among cancer patients in Israel have not been published. The aim of this study was to characterize Covid-19 disease patterns among cancer patients treated at a tertiary center. Methods: Cancer patients positive for Covid-19 between March and October 2020 (including the 1st and 2nd outbreaks) were identified by crossing the databases of the oncology clinic with those of the test data performed at the hospital and in the community. Clinical and demographic data were collected from the medical records. Results: During the study period, 60 cancer patients, out of ~12,000 were identified as positive for Covid-19. Three additional asymptomatic patients were identified by a mandatory screening program established for patients being hospitalized at the oncology department. Of all patients who were diagnosed as positive for Covid-19, 29 (48%) were defined as having a severe disease and 10 (34%) of them died during the data collection period. Those with severe illness were significantly older (71 vs 59 years old p-0.001) and more of them had metastatic disease (47% vs. 53% p-0.01). No significant associations were found between the type of cancer, type of oncology treatment and the severity of Covid-19. Among patients who received active treatment, a delay in treatment was observed for a median time of 17 days. Discussion: Our data indicate relatively low incidence of Covid-19 infection among actively treated cancer patients, possibly due to strict adherence of these patients to social distancing rules. As no association was noted between Covid-19 severity and the oncology treatment, it is probably appropriate to continue optimal cancer care and avoid treatment interruptions even in times of Covid-19 outbreaks.
MeSH term(s)	COVID-19 ; Humans ; Israel/epidemiology ; Middle Aged ; Neoplasms/epidemiology ; Neoplasms/therapy ; Pandemics ; SARS-CoV-2
Language	Hebrew
Publishing date	2022-01-25
Publishing country	Israel
Document type	Journal Article
ZDB-ID	953872-0
ISSN	0017-7768
ISSN	0017-7768
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 291: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [A DELICATE BALANCE OF ONCOLOGY PRACTICE DURING THE COVID-19 PANDEMIC].

Waissengrin, Barliz / Wolf, Ido

Harefuah

2020 Volume 159, Issue 12, Page(s) 867–869

Abstract: Background: The SARS-COV-2 virus emerged in Israel in March 2020 and compelled restructuring of the Israeli health care system. Despite the paucity of data, it appears that oncology patients suffer from a higher risk of complications due to COVID-19 ... ...

Abstract	Background: The SARS-COV-2 virus emerged in Israel in March 2020 and compelled restructuring of the Israeli health care system. Despite the paucity of data, it appears that oncology patients suffer from a higher risk of complications due to COVID-19 infection, including hospitalization in the intensive care unit (ICU) and death. A delicate balance exists between the oncologists' obligation to provide optimal and effective cancer treatment and the risks enveloping treatment that may place patients vulnerable to contraction of the virus. In an effort to reorganized oncological units, guidelines were published by the American and European oncology unions (ASCO, ESMO), including cancellation of frontal meetings, converting to telemedicine and changes in treatment protocols mitigating the exposure of patients to hospital visitations. Khoury et al. reported their experiences and challenges at Bnai Zion Hospital in Haifa during the first days of the pandemic, recounting the protection of staff, patients and reorganization of the oncological unit.
MeSH term(s)	COVID-19 ; Humans ; Israel/epidemiology ; Neoplasms/epidemiology ; Neoplasms/therapy ; Pandemics/prevention & control ; SARS-CoV-2
Language	Hebrew
Publishing date	2020-12-23
Publishing country	Israel
Document type	Journal Article
ZDB-ID	953872-0
ISSN	0017-7768
ISSN	0017-7768
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 291: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.

Ligumsky, Hagai / Amir, Sharon / Arbel Rubinstein, Tamar / Guion, Kate / Scherf, Tali / Karasik, Avraham / Wolf, Ido / Rubinek, Tami

Medical oncology (Northwood, London, England)

2024 Volume 41, Issue 6, Page(s) 138

Abstract: Breast cancer (BC) is associated with type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide (GLP)-1 regulates post-prandial insulin secretion, satiety, and gastric emptying. Several GLP-1 analogs have been FDA-approved for the treatment of ... ...

Abstract	Breast cancer (BC) is associated with type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide (GLP)-1 regulates post-prandial insulin secretion, satiety, and gastric emptying. Several GLP-1 analogs have been FDA-approved for the treatment of T2DM and obesity. Moreover, GLP-1 regulates various metabolic activities across different tissues by activating metabolic signaling pathways like adenosine monophosphate (AMP) activated protein kinase (AMPK), and AKT. Rewiring metabolic pathways is a recognized hallmark of cancer, regulated by several cancer-related pathways, including AKT and AMPK. As GLP-1 regulates AKT and AMPK, we hypothesized that it alters BC cells' metabolism, thus inhibiting proliferation. The effect of the GLP-1 analogs exendin-4 (Ex4) and liraglutide on viability, AMPK signaling and metabolism of BC cell lines were assessed. Viability of BC cells was evaluated using colony formation and MTT/XTT assays. Activation of AMPK and related signaling effects were evaluated using western blot. Metabolism effects were measured for glucose, lactate and ATP. Exendin-4 and liraglutide activated AMPK in a cAMP-dependent manner. Blocking Ex4-induced activation of AMPK by inhibition of AMPK restored cell viability. Interestingly, Ex4 and liraglutide reduced the levels of glycolytic metabolites and decreased ATP production, suggesting that GLP-1 analogs impair glycolysis. Notably, inhibiting AMPK reversed the decline in ATP levels, highlighting the role of AMPK in this process. These results establish a novel signaling pathway for GLP-1 in BC cells through cAMP and AMPK modulation affecting proliferation and metabolism. This study suggests that GLP-1 analogs should be considered for diabetic patients with BC.
MeSH term(s)	Humans ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Exenatide/pharmacology ; Female ; Liraglutide/pharmacology ; Glucagon-Like Peptide 1/metabolism ; Glucagon-Like Peptide 1/pharmacology ; Glucagon-Like Peptide 1/analogs & derivatives ; Cell Line, Tumor ; AMP-Activated Protein Kinases/metabolism ; Signal Transduction/drug effects ; Cell Survival/drug effects ; Warburg Effect, Oncologic/drug effects ; Cell Proliferation/drug effects ; Venoms/pharmacology ; Adenylate Kinase/metabolism ; Peptides/pharmacology
Chemical Substances	Exenatide (9P1872D4OL) ; Liraglutide (839I73S42A) ; Glucagon-Like Peptide 1 (89750-14-1) ; AMP-Activated Protein Kinases (EC 2.7.11.31) ; Venoms ; Adenylate Kinase (EC 2.7.4.3) ; Peptides
Language	English
Publishing date	2024-05-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	1201189-7
ISSN	1559-131X ; 0736-0118 ; 1357-0560
ISSN (online)	1559-131X
ISSN	0736-0118 ; 1357-0560
DOI	10.1007/s12032-024-02390-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1899: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Oncologic patients' misconceptions may impede enrollment into clinical trials: a cross-sectional study.

Asher, Nethanel / Raphael, Ari / Wolf, Ido / Pelles, Sharon / Geva, Ravit

BMC medical research methodology

2022 Volume 22, Issue 1, Page(s) 5

Abstract: Background: Clinical trials are an essential source for advances in oncologic care, yet the enrollment rate is only 2-4%. Patients' reluctance to participate is an important barrier. This study evaluates patients' level of understanding and attitudes ... ...

Abstract	Background: Clinical trials are an essential source for advances in oncologic care, yet the enrollment rate is only 2-4%. Patients' reluctance to participate is an important barrier. This study evaluates patients' level of understanding and attitudes towards clinical trials. Methods: This cross-sectional study was conducted in the oncology department and day care unit at the oncology division Tel Aviv Sourasky Medical Center, Israel. From January 2015 to September 2016. Two-hundred patients' currently receiving active anti-cancer therapy at a large tertiary hospital completed an anonymous questionnaire comprised of demographic information, past experience in clinical research and basic knowledge on clinical trials. Results: The majority of respondents did not meet the minimum knowledge level criteria. In those who replied they would decline to participate in a clinical trial, concern were related to potential assignment to the placebo arm, provision of informed consent and trust issues with their oncologist. Those with sufficient knowledge were significantly more interested in participating. Patients with past experience in clinical trials had a higher level of academic education, were less religious, had a better understanding of medical research and were inclined to participate in future research. Conclusions: Misperceptions of clinical trials may contribute substantially to the unwillingness to participate in them.
MeSH term(s)	Clinical Trials as Topic ; Cross-Sectional Studies ; Humans ; Informed Consent ; Neoplasms/therapy ; Patient Participation/psychology ; Surveys and Questionnaires
Language	English
Publishing date	2022-01-07
Publishing country	England
Document type	Journal Article
ZDB-ID	2041362-2
ISSN	1471-2288 ; 1471-2288
ISSN (online)	1471-2288
ISSN	1471-2288
DOI	10.1186/s12874-021-01478-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Less Is More: Polypharmacy at the End of Life.

Barak, Renana / Waissengrin, Barliz / Wolf, Ido

The Israel Medical Association journal : IMAJ

2021 Volume 23, Issue 7, Page(s) 452–453

MeSH term(s)	Antineoplastic Agents/therapeutic use ; Critical Pathways/statistics & numerical data ; Humans ; Neoplasm Staging ; Neoplasms/drug therapy ; Neoplasms/mortality ; Neoplasms/pathology ; Neoplasms/psychology ; Palliative Care/methods ; Palliative Care/psychology ; Polypharmacy ; Psycho-Oncology ; Terminal Care/ethics ; Terminal Care/methods ; Terminal Care/psychology
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2021-07-11
Publishing country	Israel
Document type	Editorial
ZDB-ID	2008291-5
ISSN	1565-1088 ; 0021-2180
ISSN	1565-1088 ; 0021-2180
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5470: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: In Reply.

Wolf, Ido / Waissengrin, Barliz / Pelles, Sharon

The oncologist

2020 Volume 25, Issue 11, Page(s) e1817

MeSH term(s)	Epidemics ; Humans ; Telemedicine
Language	English
Publishing date	2020-09-14
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1634/theoncologist.2020-0627
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Breaking Bad News via Telemedicine: A New Challenge at Times of an Epidemic.

Wolf, Ido / Waissengrin, Barliz / Pelles, Sharon

The oncologist

2020 Volume 25, Issue 6, Page(s) e879–e880

MeSH term(s)	Communication ; Epidemics ; Female ; Humans ; Middle Aged ; Physician-Patient Relations ; Telemedicine/ethics ; Telemedicine/methods ; Truth Disclosure/ethics
Keywords	covid19
Language	English
Publishing date	2020-04-28
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1634/theoncologist.2020-0284
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: First-Line Efficacy of Anti-HER2 Treatments in Previously Treated HER2-Positive Metastatic Breast Cancer Patients: A Retrospective Observational Study Investigating the Efficacy of Re-Exposure to Anti-HER2 Therapy for HER2-Positive Metastatic Breast Cancer Patients in Comparison with Naïve Patients.

Waissengrin, Barliz / Levin, Roni / Wolf, Ido / Shachar, Eliya / Sonnenblick, Amir

Breast care (Basel, Switzerland)

2021 Volume 17, Issue 2, Page(s) 146–152

Abstract: Background: Most patients with HER2-positive metastatic breast cancer (MBC) receive first-line treatment with anti-HER2 agents and have already received anti-HER2 therapy as adjuvant or neoadjuvant therapy in the local setting of their disease ... ...

Abstract	Background: Most patients with HER2-positive metastatic breast cancer (MBC) receive first-line treatment with anti-HER2 agents and have already received anti-HER2 therapy as adjuvant or neoadjuvant therapy in the local setting of their disease presentation. Despite that, they constitute only a minority among clinical trials, and their response to reintroduction to anti-HER2 treatments is inconclusive based upon conflicting studies. We aimed to examine if previous exposure influences the clinical outcome of patients treated with anti-HER2 treatments compared to patients who were naïve to anti-HER2 agents. Methods: We conducted a retrospective observational study of HER2-positive MBC patients who were treated with trastuzumab and pertuzumab from 2014 to 2018. We collected and analyzed data including patients' demographic characteristic as well as extracted data of previous treatment regimens and the efficiency of the anti-HER2 therapy measured by response rate (RR), time to tumor progression (TTP), and overall survival (OS). Results: Eighty patients met the inclusion criteria, 26 (32.5%) of them were previously exposed to anti-HER2 treatments and 54 (67.5%) were not previously exposed to anti-HER2 therapy. No significant differences were detected in RR after 3 months of treatment ( Conclusion: Our analysis suggests that previous exposure to anti-HER2 agents might influence the clinical outcome of first-line treatment in metastatic HER2 patients. These findings justify further exploration of the benefit of reintroduction of anti-HER2 treatment enabling the optimal treatment for patients with previous anti-HER2 therapy exposure.
Language	English
Publishing date	2021-07-07
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2202236-3
ISSN	1661-3805 ; 1661-3791
ISSN (online)	1661-3805
ISSN	1661-3791
DOI	10.1159/000516936
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6620: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito